NCT06161532View on ClinicalTrials.gov

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2028

Conditions
Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the BladderSquamous Cell Carcinoma of the Urinary TractPrimary Adenocarcinoma of the BladderPrimary Adenocarcinoma of the Urinary TractRenal Medullary CarcinomaSquamous Cell Carcinoma of the Penis
Interventions
DRUG

Sacituzumab govitecan

Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.

DRUG

Atezolizumab

Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH